Active Run Stocks Logging Brokers’ Choice: Sandstorm Gold (NYSE:SAND), Novartis (NYSE:NVS)

Shares of Sandstorm Gold Ltd. (NYSE:SAND) [Trend Analysis] swings enthusiastically in regular trading session, it an advance of 0.70% to close at $4.32. Sandstorm Gold Ltd. (NYSEMKT:SAND) has acquired 22 net smelter return (“NSR”) royalties during the first quarter of 2017 for consideration of US$1.9 million. The assets include royalties on development-stage, advance exploration-stage and exploration-stage projects located in Canada, Mexico and Peru.

“The collection of royalties that we have acquired so far in 2017 have added exploration potential in stable jurisdictions, increasing the optionality in our portfolio which is now up to 155 streams and royalties,” said Sandstorm President and CEO. Watson added, “We have over $30 million in cash and $110 million accessible on our revolving line of credit and we are working diligently to continue deploying our capital into accretive acquisitions that will add value to shareholders.” The stock is going forward its fifty-two week low with 43.52% and lagging behind from its 52-week high price with -36.00%. SAND last month stock price volatility remained 6.12%.

Novartis AG (NYSE:NVS) [Trend Analysis] retains strong position in active trade, as shares scoring -0.38% to $74.15 in active trade session, while looking at the shares volume, around 225215 shares have changed hands in this session. Alcon, a division of Novartis, reported it has received approval from the US FDA for its AcrySof IQ ReSTOR +2.5 Multifocal Toric intraocular lens with ACTIVEFOCUS optical design for patients undergoing cataract surgery who choose to address their astigmatism and presbyopia at the same time.

Alcon plans to commercialize the ACTIVEFOCUS toric intraocular lens in the US beginning in mid-2017.The company noted that its ACTIVEFOCUS toric IOL is the only multifocal toric IOL in which the central portion is 100 percent dedicated to distance vision. The unique optical design of the ACTIVEFOCUS toric IOL gives astigmatic cataract patients quality distance vision and an surged range of vision to potentially reduce dependence on glasses. The firm has institutional ownership of 10.70%, while insider ownership included 9.30%. NVS attains analyst recommendation of 2.00 with week’s performance of -1.64%. Investors looking further ahead will note that the Price to next year’s EPS is 9.77%.

 

About Devon Leftovich

Leave a Reply

Your email address will not be published. Required fields are marked *